HIV medication costs between roughly $80 and $4,700 per month at list price, depending on which drug is prescribed. The most commonly prescribed single-tablet regimens fall in the $3,000 to $4,200 range before insurance or assistance programs. However, very few people pay full price. Between insurance coverage, government programs, and manufacturer assistance, most people living with HIV pay significantly less out of pocket, and many pay nothing at all.
List Prices for Common HIV Medications
HIV treatment today typically involves taking one pill per day that combines multiple active ingredients into a single tablet. These combination pills vary widely in cost. The wholesale acquisition cost, which is the list price manufacturers charge wholesalers, gives a clear picture of the price range:
- Biktarvy (the most widely prescribed): $4,216/month
- Genvoya: $4,216/month
- Symtuza: $4,717/month
- Triumeq: $3,897/month
- Odefsey: $3,840/month
- Dovato: $3,096/month
- Delstrigo: $2,800/month
- Generic efavirenz combinations: $82 to $252/month
That’s the sticker price. It doesn’t reflect what most people actually pay, but it’s the number that drives insurance negotiations, copay amounts, and out-of-pocket maximums. At list price, a year on Biktarvy runs over $50,000. The generic option brings annual costs under $3,000, though it uses an older drug combination that doctors prescribe less frequently due to side effects.
Injectable Treatment Costs More
For people who prefer not to take a daily pill, Cabenuva is a long-acting injectable given every one or two months at a clinic. The U.S. list price exceeds $48,000 per year, making it one of the most expensive HIV treatment options. In Canada, the same drug lists at about $25,800 annually. The higher cost reflects both the medication itself and the clinical infrastructure needed: refrigerated storage, scheduled clinic visits, and provider administration of each injection.
What You Actually Pay With Insurance
Most people with insurance pay far less than list price. Under the Affordable Care Act, private insurance plans must cover HIV treatment, though your copay or coinsurance depends on your plan’s formulary tier. Medicare Part D is required to include all antiretrovirals on its formulary, meaning no HIV medication can be excluded from coverage. This is an unusual protection that applies to only a handful of drug categories.
Even with insurance, copays for brand-name HIV drugs can still run hundreds of dollars per month if the medication lands on a higher formulary tier. That’s where manufacturer copay assistance programs become essential.
Manufacturer Copay Programs
The two largest HIV drug manufacturers, Gilead Sciences and ViiV Healthcare, both offer copay assistance cards that cover most or all of your remaining out-of-pocket costs after insurance pays its share.
Gilead’s copay program covers up to $7,200 per year for Biktarvy and up to $6,000 per year for several other medications. ViiV’s program covers up to $7,500 per year for Triumeq and up to $6,250 per year for Dovato. For the injectable Cabenuva, ViiV offers up to $13,000 per year in cost-sharing assistance, plus up to $100 per injection for the provider’s administration fee. These programs are available to commercially insured patients and can reduce your copay to zero in many cases.
Both companies also run patient assistance programs for people who are uninsured or underinsured, providing medication at no cost to those earning below 500% of the federal poverty level.
Government Programs for Uninsured Patients
The Ryan White HIV/AIDS Program is the federal safety net for people living with HIV who have no insurance or whose insurance leaves gaps. It covers medications, doctor visits, lab work, mental health services, dental care, and even help paying insurance premiums. To qualify, you need an HIV diagnosis, low income based on your state’s threshold, and inadequate insurance coverage.
Within Ryan White, the AIDS Drug Assistance Program (ADAP) specifically covers the cost of HIV medications. Income eligibility varies by state, but it’s more generous than many people expect. Out of 49 programs that reported data in 2023, 29 set their income cutoff at 500% of the federal poverty level or higher. That means a single person earning roughly $73,000 or more could still qualify in the majority of states. Another 17 programs set the cutoff between 300% and 400% of FPL. Only three programs used a threshold below 300%.
Between ADAP, Medicaid, manufacturer programs, and nonprofit grants (such as the Patient Advocate Foundation, which offers up to $5,000 per year for copays and deductibles), there is a layered system designed to ensure that cost does not prevent anyone from accessing HIV treatment.
Costs Beyond the Medication
The price of the pills is only part of the picture. Staying on HIV treatment requires regular monitoring, typically every three to six months. Each visit involves blood work to check your viral load (whether the virus is suppressed) and your immune cell counts. A viral load test costs roughly $30, while a CD4 immune cell count runs about $5. With insurance, these labs are usually covered as part of routine care. Without insurance, the Ryan White Program covers them as core medical services.
You may also have costs for the initial clinic visits, annual checkups, and any additional prescriptions for related conditions. For people on injectable treatment like Cabenuva, clinic visit fees for each injection add to the total, though manufacturer programs often help offset those charges.
PrEP Costs for HIV Prevention
If you searched for HIV medication costs because you’re considering prevention rather than treatment, the pricing landscape is different. The Affordable Care Act requires commercial insurance plans and Medicaid expansion programs to cover PrEP with zero cost-sharing: no copay, no coinsurance, no deductible. As of October 2024, Medicare Part B also covers PrEP medication and related services, including the fee for administering injectable PrEP.
For uninsured individuals, Gilead offers a copay savings program covering prescription costs for its PrEP medications, and ViiV’s savings program covers up to $7,500 per year for the injectable PrEP option Apretude. The practical result is that most people in the U.S. can access PrEP at little or no personal cost, regardless of insurance status.